REDWOOD CITY, Calif.--(BUSINESS WIRE)--PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced a series of new commercial partnerships and distribution agreements ...

After a tough third quarter in which Emergent BioSolutions cut more than $100 million from its revenue guidance, the company is gaining some much-needed cash with an asset sale to Bavarian Nordic.

GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic ...

Emergent Travel Health will temporarily discontinue the manufacture and distribution of Vaxchora and Vivotif in the US due to a significant reduction in international travel due to the COVID-19 ...

In a two-step scheme, specialty vaccine developer Paxvax Inc. acquired the FDA-approved oral typhoid vaccine Vivotif from Crucell Switzerland AG and financed the deal with $50 million in secured debt ...

Bavarian Nordic A/S plans to buy two travel vaccines plus a phase III chikungunya vaccine candidate from Emergent Biosolutions Inc. for about $380 million. Emergent will receive a $270 million ...